CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

December 15, 2023

https://www.prnewswire.com/news-releases/cymabay-submits-new-drug-application-to-fda-for-seladelpar-for-the-treatment-of-primary-biliary-cholangitis-302016212.html

– NDA is supported by data evaluating seladelpar efficacy and safety in over 500 patients – 

– Seladelpar is the first New Drug Application from CymaBay in its ongoing mission to help people living with PBC – 

Read more at prnewswire.com

Related news for (CBAY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.